IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer (Neonab)
Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer
Sponsor: Barwon Health
A PHASE2 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by Barwon Health and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Barwon Health
For direct contact, visit the study record on ClinicalTrials.gov .